our current teaching faculty are familiar with the concept of palliative care. Very few medical colleges in India have access to palliative care centers to demonstrate the attitude and skill aspects of palliative care competencies. There is a high chance that the focus will be on the knowledge aspect, confined to classroom teaching, with few case scenarios being discussed, by those who are not exposed to palliative care and its complexities. If not introduced properly, the palliative approach that intends to improve the quality of life of patients and their families facing the problem associated with life-threatening illness by addressing their physical, psychosocial and spiritual needs, will get misrepresented among medical students as end of life or "giving up." This may not be very much different from their current understanding of palliative care.
The rising prevalence of chronic debilitating conditions is definitely throwing a major challenge to the overburdened healthcare system in India. These debilitating conditions, coupled with an increase in the elderly population, are going to cause a rise in palliative care needs. Although palliative components in CBME are the right step, it is not enough. It is important that the existing medical fraternity has to be familiarized correctly with the palliative approach, for it to trickle down properly to the rest.
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Cebranopadol: A First-in-Class Nociceptin Receptor Agonist for Managing Chronic Pain
Sir, Nociceptin/orphanin FQ (N/OFQ) peptide receptor or NOP receptor is a member of opioid receptors, such as mu-opioid peptide (MOP), delta-opioid peptide, and kappa-opioid peptide (KOP) receptor. [1] NOP receptor and its ligand N/OFQ have been extensively studies in the last two decades. Just like opioid receptors, NOP receptors are spread extensively in the central and peripheral nervous systems. Like opioid receptors, NOPs are also G-protein coupled receptors. Subsequently, selective NOP receptor agonists were studies for use in pain management to avoid adverse effects of routinely used MOP receptor agonists. Till date, they have not been approved for clinical use.
MOP receptor agonists are considered gold standard for managing acute pain and chronic pain of cancer and certain noncancer origin. However, there are undesirable effects such as constipation, nausea/vomiting, sedation, tolerance, and addiction, which are related to dose and duration of use. Use of agents with combined NOP and MOP receptor agonist activity has been described which has better analgesic profile and lesser side effects.
Cebranopadol is a novel, centrally acting, potent, first-in-class analgesic drug, which acts by dual-mechanism, i.e. NOP receptor and MOP receptor agonism. [2] It has partial activity toward KOP receptor also. In spite of MOP and KOP receptor agonistic properties, the clinical effects of cebranopadol are not similar to these receptors agonism, i.e., it has lesser or minimal adverse effect profile with similar analgesia properties. Experimental studies have shown efficacy of cebranopadol in chronic cancer pain, inflammatory conditions such as osteoarthritis, neuropathic pain such as low back ache, and certain acute nociceptive pain also. [3] Chemically, cebranopadol is trans-6,9-fluoro- 4,9,9,9- Figure 1 ]. In experimental studies, it has been found useful in managing acute postoperative pain, chronic neuropathic pain such as low back ache, diabetic neuropathy, and cancer pain. It has been used intravenously (IV) and orally in several studies. [4] Cebranopadol binds to NOP and MOP receptors with equal affinity and provides good-quality analgesia in animal studies and humans. The drug was better tolerated at various doses when administered orally (200, 400, and 600 µg) and did not appear to cause respiratory depression, nausea, vomiting, or sedation at above-mentioned doses. [5] It is a long-acting drug, and therefore, a single dose in 24 h has been shown to be effective in many varieties of pain model. The plasma half-life when used IV is around 4.5 h. After an IV injection at a dose ranging from 0.5 to 5.6 µg/kg, the pain relief lasted for up to 7 h. The efficacy and duration of analgesia are different in different conditions. Compared to an oral dose of 200 µg/day, patients who received 400 and 600 µg had better pain relief and less rescue analgesic requirements. [6] In human studies, there was no manifestation of withdrawal symptoms noted when cebranopadol was abruptly discontinued after around 14 weeks of clinical use. However, the US-FDA approval is still due.
In conclusion, cebranopadol is a novel centrally acting opioid which appears to have a better profile compared to MOP receptor agonists and various partial agonists, which are quite popular in clinical practice. Results on ongoing studies are awaited which might guide clinicians in using it in specific situations that can have cost-effective, favorable outcomes.
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